Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 30Sarcoma 5CNS 4Thoracic 3Tumor-Agnostic 2Other solid neoplasm 2Gynecologic 2Endocrine 2

Conditions

Uterine Cervical Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 35Bevacizumab 31Carboplatin 29pembrolizumab 25Specimen Handling 20Magnetic Resonance Spectroscopy 18olaparib 16Cisplatin 15liposomal doxorubicin 13Taxes 12Immunoglobulin G 11Gemcitabine 11Disulfides 11Topotecan 9Nivolumab 9Cyclophosphamide 9Biopsy 8fludarabine 7Doxorubicin 7mirvetuximab soravtansine 6niraparib 5Radiation 5Oxaliplatin 5Fulvestrant 5Fluorouracil 5trastuzumab deruxtecan 4durvalumab 4cediranib 4Platinum 4Megestrol Acetate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Irinotecan × Gynecologic × 30 days × Clear all
NCT06459180 2026-05-27

TroFuse-020

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
686 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
750 enrolled
GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡